Commitments, Contingencies, and Collaborations - Lepu (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Jan. 21, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Agreement | |||||
| Research and development | $ 42,339 | $ 27,720 | $ 79,957 | $ 89,009 | |
| License Agreement | Lepu Biopharma | |||||
| Agreement | |||||
| Cash payment | $ 40,000 | ||||
| Maximum amount payable upon achievement of development and regulatory milestones | 280,000 | ||||
| Maximum amount payable upon achievement of commercial milestones | $ 890,000 | ||||
| Milestone payments paid | 1,000 | 6,000 | |||
| Milestone payments earned | 12,000 | ||||
| Research and development | $ 2,300 | $ 200 | $ 3,300 | $ 200 | |
| X | ||||||||||
- Definition Maximum amount payable upon achievement of commercial milestones. No definition available.
|
| X | ||||||||||
- Definition Maximum amount payable upon achievement of certain development and regulatory milestone events. No definition available.
|
| X | ||||||||||
- Definition Amount of cash outflow for cash payment made in relation to the agreement. No definition available.
|
| X | ||||||||||
- Definition Amount of milestone payments made during the period. May include clinical, regulatory and commercial milestone payments. No definition available.
|
| X | ||||||||||
- Definition Amount of milestone payments earned but not yet paid during the period. May include clinical, regulatory and commercial milestone payments. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|